StockData
Oncolytics Biotech Inc logo

Oncolytics Biotech Inc (ONCY) company profile

ONCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 0/30
$0.38+0.04 (+12.53%)

Close on Nov 17, 2026Market cap $48.77MP/E –Yield –

About Oncolytics Biotech

Pharmaceutical Preparations, SIC 2834

Oncolytics Biotech is a clinical-stage biopharmaceutical enterprise focused on developing pelareorep, an intravenously administered immunotherapeutic candidate. Pelareorep is a proprietary isolate of reovirus designed to replicate selectively inside RAS-mutated tumor cells, stimulate innate and adaptive immune defenses, and transform the immunosuppressive microenvironment of solid tumors. The firm prioritizes platform development for gastrointestinal malignancies—including pancreatic ductal adenocarcinoma, anal canal carcinoma, and metastatic colorectal cancer—alongside clinical evaluations in breast cancer. These investigational programs aim to improve clinical responses when paired with chemotherapy or checkpoint inhibitors. Target beneficiaries comprise oncology patients who have exhausted or derived minimal benefit from current standard cancer therapies.

The enterprise conducts its research programs internationally across multiple jurisdictions, utilizing external study sites and clinical collaborations throughout North America. It manages a portfolio of 137 patents spanning the United States, Canada, and other foreign regions. Manufacturing operations rely principally on a single toll manufacturer located within the United States to supply clinical-grade active ingredients and formulated drug products. The provided text contains no details disclosing the company's corporate headquarters location.

Summary of the business section of Oncolytics Biotech's latest annual report, written by StockData.

Company profile

Company

Legal name
Oncolytics Biotech Inc
Founded
1998
Headquarters
San Diego, CA
Address
Suite 325, 4350 Executive Drive 92121
Phone
(403) 670-7377
Employees
29, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Calgary, Canada

Stock & identifiers

Ticker
ONCY
Exchange
Nasdaq
IPO date
Oct 5, 2001
Shares outstanding
128M, Aug 10, 2026
Public float
$72.10M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-9.5 reverse, Mar 15, 2019; 1-for-9.5 reverse, May 25, 2018
SEC CIK
1129928
CUSIP
68237V103
ISIN
US68237V1035
FIGI
BBG000DVS826
Share class FIGI
BBG001SDGSF3
EIN
98-0541667

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jared KellyChief Executive Officer, Director114,050
John Bearden McAdoryChief Operating Officer–
Kirk LookChief Financial Officer287,515
Allison HagermanChief Technology Officer115,059
Thomas Charles HeinemanChief Medical Officer282,818
Andrew AromandoChief Business Officer55,100
Deborah Margaret BrownDirector109,851
Stephen C. GloverDirector–
Angela HolthamDirector183,639
Jonathan RigbyDirector42,728
Wayne PisanoDirector492,414
James T. ParsonsDirector41,849
Bernd R. SeizingerDirector566,991
Patricia S. AndrewsDirector78,128

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Kelly
$2.11M$6.04M$1.16M$65–
FY2025
Pisano
$433.14K$464.74K$1.16M$65–
FY2024
Coffey
$739.61K$406.97K$731.48K$68–
FY2024
Pisano
$233.78K$214.16K$731.48K$68–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jared Kelly
Chief Executive Officer
$318.09K–$1.78M–$9.58K$2.11M–
Wayne Pisano
Former Interim CEO
$110.00K$124.42K$108.72K$50.00K$40.00K$433.14K+85%
Thomas C. Heineman
Chief Medical Officer
$550.97K–$521.87K$110.50K$14.00K$1.20M+51%
Kirk Look
Chief Financial Officer
$460.98K–$547.05K$90.50K$23.71K$1.12M+67%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 29 total and full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?